Today we recognize Glanzmann Thrombasthenia (GT) Awareness Day. Living with GT means facing the daily challenge of a life-threatening bleeding disorder that affects the body’s ability to form blood clots, making even minor injuries potentially catastrophic. The impact on individuals and families is profound, both physically and emotionally. For over 100 years, there has been little progress in effective treatments for GT, leaving those affected without viable options. At Hemab, we’re committed to breaking this cycle of stagnation. We are advancing research and developing therapies that aim to improve the lives of those living with GT and other rare bleeding disorders. Our focus is placed on developing innovative solutions that can offer real hope for the future. Learn more about how we are advancing the first prophylactic treatment for GT at https://hemab.com/ Stay tuned this month as we continue to share our mission and raise awareness in honor of #BleedingDisordersAwarenessMonth. Together, we can amplify hope and support for the bleeding disorders community. #GlanzmannThrombastheniaAwarenessDay
It is indeed! # www.sasat.org
Great news
Fun fact, our founder Helen Smith actually played a huge role in getting this day recognized nationally!